AMSBIO Sponsor Poster Prize at Beatson Cancer Conference

AMSBIO, a provider of cutting-edge life science technologies and services for accelerating discovery in cancer research, has continued its sponsorship of the annual poster prize at the Beatson International Cancer Conference (7–10 July 2013).

The two winners of the Poster Prize for the best presented and most interesting posters, were this year named as Dr Thomas R. Cox and co-researchers** for their work on ‘Deep proteomic analysis of the hypoxic secretome lysyl oxidase as a critical mediator of metastatic lesion formation in bone’, and Dr Jean Albrengues & co-researchers*** for their work on ‘Production of LIF cytokine by cancer cells and fibroblasts contributes to the establishment of a pro-invasive tumour microenvironment’.

As one of Cancer Research UK’s core-funded institutes, the Beatson Institute (www.beatson.gla.ac.uk/)  performs a programme of world-class science directed at understanding key aspects of cancer cell behaviour, and tries to translate these discoveries into new therapies and diagnostic/prognostic tools to help cancer patients. The Institute benefits from close interactions with the University of Glasgow, including strong links with the University’s Institute of Cancer Sciences.

AMSBIO is a rapidly growing company focused on the supply and development of products and technology for cancer research with emphasise on apoptosis, DNA damage and repair, and cancer cell function and behavior. AMSBIO supplies focused research products for cancer research that allow researchers to study cancer cell function and behavior including in angiogenesis, cell invasion and PARP and PARG research. Together with specifically designing assays for lead compound and genotoxic screening based on DNA damage and repair and cancer cell behavior, AMSBIO is establishing itself as a leading international provider of cancer research tools and services.

 ** Thomas R Cox1,2, Erwin M Schoof3, Demelza Bird2, Norain Ab Latif4, Antika Agrawal4, Holly R Evans4, Iain D Huggins4, Robin MH Rumney4, Georgina Lang2, Rune Linding3, Alsion Gartland4 and Janine T Erler1,2.

1 Biotech Research & Innovation Centre (BRIC), University of Copehagen, Denmark

2 Cancer Research UK Tumour Cell Signalling Unit, The Institute of Cancer Researh, London, UK

3 Cellular Signal Integration Group, Department of Systems Biology, Technical University of Denmark, Denmark.

4 The Mellanby Centre for Bone Research, The University of Sheffield, Sheffield, UK

***  Jean Albrengues1, Isabelle Bourget1, Catherine Pons1, Vincent Butet2, Sophie Tartare-Deckert3, Chloe Feral1, Guerrino Meneguzzi1 and Cedric Gaggioli1

1 INSERM, U1081, CRNS, UMR7284, Institute for Research on Cancer & Aging in Nice (IRCAN), University of Nice Sophia Antipolis, Medical School, 28 Avenue de Valombrose, F-06107, Nice, France.

2 Pathological anatomy & cytology laboratory, 270 Avenue Sainte-Marguerite, F-06200, Nice, France.

3 INSERM, U1065, Mediterranean Centre for Molecular Medicine (C3M), University of Nice Sophia Antipolis, Nice, France.